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ABSTRACT
Inflammation is a potent inducer of tumorigenesis. Increased DNA damage 
or loss of genome integrity is thought to be one of the mechanisms linking 
inflammation and cancer development. It has been suggested that NF-κB-induced 
microRNA-146 (miR146a) may be a mediator of the inflammatory response. Based 
on our initial observation that miR146a overexpression strongly increases DNA 
damage, we investigated its potential role as a modulator of DNA repair. Here, we 
demonstrate that FANCM, a component in the Fanconi Anemia pathway, is a novel 
target of miR146a. miR146a suppressed FANCM expression by directly binding to the  
3’ untranslated region of the gene. miR146a-induced downregulation of FANCM was 
associated with inhibition of FANCD2 monoubiquitination, reduced DNA homologous 
recombination repair and checkpoint response, failed recovery from replication stress, 
and increased cellular sensitivity to cisplatin. These phenotypes were recapitulated 
when miR146a expression was induced by overexpressing the NF-κB subunit p65/
RelA or Helicobacter pylori infection in a human gastric cell line; the phenotypes were 
effectively reversed with an anti-miR146a antagomir. These results suggest that 
undesired inflammation events caused by a pathogen or over-induction of miR146a 
can impair genome integrity via suppression of FANCM.
INTRODUCTION
Chronic inflammation is believed to be a causative 
factor for tumorigenesis. NF-κB is a crucial regulator of 
the inflammatory response. Its constitutive or transient 
activation enables genetic alterations and oncogene 
activation, and confers cancer-promoting potential to cells 
[1]. NF-κB forms multiple homodimeric- or heterodimeric 
complexes with Rel-like domain-containing proteins, 
including RelA/p65. It is a pleiotropic transcription factor 
that can exert profound effects on the cellular immune state 
by coordinating the expression of numerous downstream 
targets [2, 3]. MicroRNA-146a (miR146a), recognized 
as a gene targeted by NF-κB, has been implicated in a 
variety of cellular functions, particularly in pathological 
conditions, such as inflammation and cancer [4–6]. 
Chronic inflammation caused by a variety of pathogens 
such as Helicobacter pylori (H. pylori) can presumably 
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induce the long term expression of NF-κB and miR146a 
[7–9]. This study investigated the potential influence of 
H. pylori infection, activation of NF-κB, and miR146a on 
cellular genome integrity and tumorigenesis.
MicroRNAs (miRNAs) are small non-coding 
RNAs with approximately 20–24 nucleotides in length 
that repress gene expression, usually by targeting the 
3ʹ-untranslated regions (3′UTRs) of specific mRNAs. 
Over the past decade, in silico screening of the sequencing 
database combined with reporter gene-based assays has 
led to the discovery of miRNAs targeting genes of interest. 
Mounting evidence suggests that the functions of a number 
of key factors involved in DNA repair are also regulated 
by miRNAs. 
The Fanconi anemia (FA)-associated DNA damage 
response pathway is a crucial DNA repair mechanism 
that resolves DNA interstrand crosslinked (ICL) lesions 
and stalled replication forks [10]. A key regulatory event 
in the pathway is the monoubiquitination of Fanconi 
anemia complementation group D2 (FANCD2), which is 
induced by an E3 ubiquitin ligase complex  consisting of 
8 FA proteins, including Fanconi anemia group M protein 
(FANCM) [11]. Monoubiquitinated FANCD2 forms foci at 
damaged lesions that co-localizes with DNA repair factors 
such as FANCI, BRCA1, and RAD51 [12]. Among the 
several reported roles of  monoubiquitinated FANCD2 
is recruiting the carboxy-terminal binding protein-
interacting protein (CtIP) nuclease, which induces end 
resection at double strand breaks, a step required for DNA 
homologous recombination repair (HR) and replication 
fork recovery [13–15]. FANCD2 is also essential in the 
removal and bypass of ICL-lesions by DNA replication 
machineries [16]. In addition to being part of the FA core 
complex, FANCM forms a complex with FA-associated 
protein 24 KDa (FAAP24)-MHF1-MHF2, each of which 
is required for recruitment of the FA core complex at 
chromatin and FANCD2 monoubiquitination. FAAP24 
is required for the DNA-binding and chromatin loading 
abilities of FANCM in vitro [17]. FANCM also exhibits 
ATP-dependent replication fork remodeling and branch 
migration activities using model fork structures in vitro, 
which may be needed for stabilizing DNA replication forks 
during the ICL repair [18, 19]. The fork remodeling and 
branch migration activities are enhanced by MHF1-MHF2 
in vitro [20–22]. The FANCM-FAPP24 complex also 
plays an important role in regulating ICL-induced, ATR-
mediated checkpoint [23, 24]. The roles of FANCM likely 
extend beyond the canonical FA pathway, suggested by the 
roles of FANCM orthologs in other organisms; additional 
information on this topic is summarized in a recent review 
article [25]. Overall, FANCM plays multiple roles in 
genome maintenance during replication and DNA repair. 
Here, we show that FANCM stability is directly 
regulated by miR146a. The overexpression of miR146a 
or artificial activation of NF-κB drastically suppressed 
FANCM expression, and was associated with impaired 
damage-inducible FANCD2 monoubiquitination, HR 
repair, and increased cellular sensitivity to hydroxyurea 
(HU) and cisplatin. The physiological significance of this 
pathway was supported by the observation that miR146a 
expression was induced by H. pylori infection, which 
led to reduced FANCM expression and FANCD2 foci 
formation. These data suggests the aberrant activation of 
inflammation-induced miR146a can compromise genome 
integrity by suppressing FANCM expression. 
RESULTS
miR146a directly targets the 3ʹUTR of FANCM 
It is becoming well-accepted that inflammation-
induced miR146a is associated with cancer development 
[4–6, 26]. Our initial analysis of miR146a showed that its 
overexpression strongly elicited DNA damage in HeLa 
(human cervical adenocarcinoma) and GES-1 cells (human 
gastric epithelial cells) upon treatment with the replication 
stress inducer HU and the DNA ICL-inducing agent 
cisplatin, as measured by g-H2AX foci staining (Figure 1A 
and Supplementary Figure S1A, respectively). Consistent 
with the increased damage, cells expressing miR146a 
were more sensitive to HU and cisplatin (Figure 1B and 
Supplementary Figure S1B, respectively). Moreover, co-
expression of miR-146a antagomir effectively reversed 
these phenotypes, suggesting that these effects were 
indeed mediated by miR146a. Together, these data 
suggest that overexpressing miR146a may impair genome 
integrity.
In an attempt to search for the relevant targets of 
miR146a in DNA Damage Response (DDR) or DNA 
repair, we utilized the TargetScan algorithm (MIT; 
release 6.2). This method identified several DDR genes 
as potential targets of miR146a, including BRCA1 and 
FANCM. Indeed, BRCA1 was previously identified 
as a miR146a target [27], validating our bioinformatic 
approach. To determine whether their effect of miR-146a 
on DNA damage response was mediated via its effect 
on FANCM,  we cotransfected HeLa and GES-1 cells 
with miR-146a and/or miR-146a-insensitive FANCAM 
expression plasmid. Our results showed that the non-
targetable FANCM rescued the HU-induced g-H2AX 
foci formation (Supplementary Figure S2A) and cellular 
sensitivity to HU (Supplementary Figure S2B). We also 
observed similar reversion when miR-146a-insensitive 
BRCA1 was expressed. Interestingly, when we expressed 
both FANCM and BRCA1 simultaneously, we did not see 
further rescue, indicating that FANCM and BRCA1 may 
have overlapping roles in the phenotype that we are seeing. 
Subsequent TargetScan analysis predicted that 
miR146a targeted two sequences found between 
nucleotides (nt) 704 and 711 and between nt 755 and 761 
on the human FANCM 3′UTR sequence (Figure 2A). To 
confirm the interaction of miR146a with these predicted 
sites and the subsequent repression of FANCM, we 
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Figure 1: Increase of DNA damage sensitivity by miR146a. (A) Two days after transfection of HeLa or GES-1 cells with miR146a 
alone or together with anti-miR146a, the cells were treated with 5 mM HU for 16 h to detect residual γ-H2AX. Results are shown as the 
mean ± SD (n = 3); **P < 0.01.  (B) HeLa and GES-1 cells were transfected with control, miR146a, and miR146a plus anti-miR146a, and 
were then exposed to increasing concentrations of HU for 5 hr. The viability of treated cells was examined using the clonogenic survival 
assay. Results are shown as the mean ± SD (n = 3); **P < 0.01.
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performed a 3′UTR luciferase reporter assay. The 
relative luciferase activity of the construct with wild-
type 3′UTR of FANCM significantly repressed following 
the transfection of miR146a (Figure 2B). In contrast, 
the repression of relative luciferase activity was clearly 
abrogated when single (M1 and M2) and especially double 
(M3) conserved sites were deleted in the FANCM 3′UTR. 
This indicates that these two seed regions are functional 
as miR146a targets sites, exerting additive effects on each 
other. Accordingly, the MT3 mutant was shown to be 
nonfunctional as a target of miR146a due to the complete 
loss of both target sites. 
Next, to examine the evolutionary conservation 
of the identified target sites across species, the human 
FANCM 3′UTR of 878 nt in length (GenBank accession 
number: NM_020937.3) was aligned with 100 vertebrate 
species using the algorithms provided by the UCSC 
genome browser (https://genome.ucsc.edu/index.html). 
Surprisingly, alignment data showed that the FANCM 
3′UTR was only conserved between primates, and that 
sequence differences with the other species were such 
that full sequence alignment was not allowed. While the 
two target sites of miR146a was relatively well conserved 
between primates (Supplementary Figure S3, red open 
box), neither target site was detected in species other than 
primates. These results suggest that the miR146a-mediated 
regulation of FANCM expression was introduced to the 
primate-specific FA pathway as a relatively late event in 
vertebrate evolution. 
TargetScan algorithm (MIT; release 6.2) was further 
used to generate a selective miRNA library for screening 
(Supplementary Table S1). The analysis identified a 
total of six miRNAs as candidates, each of which was 
subjected to reverse screening for gene silencing effects on 
FANCM expression using a luciferase reporter gene assay 
(Figure 2C). The results showed that miR146a expression 
led to remarkably lower luciferase activity compared 
to control miRNA, whereas weak or non-statistically 
significant effects were observed with the other tested 
miRNAs. Consistently, miR146a overexpression 
significantly reduced endogenous FANCM protein level 
in HeLa cells (Figure 2D). The effects of miR146a on 
endogenous FANCM expression was further confirmed 
by comparing its protein levels in two human cancer cell 
lines, HeLa and U2OS (osteosarcoma) cells, and two 
human gastric cell lines, HGC-27 (carcinoma) and GES-1 
(immortalized normal) cells, after transfecting the cells 
with miR146a or a negative control miRNA. As shown in 
Figure 2E, miR146a expression, which was also confirmed 
using RT-qPCR (Figure 2E, bottom), led to dramatic 
decreases in FANCM protein levels in all of the tested 
cells. BRCA1 protein expression was also downregulated, 
consistent with data from a previous study [27]. Moreover, 
expressing anti-miR146a in MCF7, HeLa and GES-1 
cells led to increases in both FANCM and BRCA1 levels 
(Supplementary Figure S4).  FANCM mRNA expression 
was also reduced when miR146a was overexpressed 
(Figure 2F), indicating that miR146a post-transcriptionally 
downregulates FANCM. These results demonstrate that 
miR146a down-regulates FANCM expression by directly 
targeting the 3′UTR of its transcript. 
miR146a expression inversely correlates with 
FANCM protein levels in several breast cancer 
cell lines
Garcia et al. [27] reported that miR146a was 
abnormally overexpressed in several breast cancer cells. 
We chose three of the cell lines described in that report to 
compare the expression patterns of endogenous miR146a 
and FANCM protein using RT-qPCR and Western blot 
analysis, respectively. While the MCF-7 and MDA-
MB-231 cell lines express wild type BRCA1, MDA-
MB-436 cells carry mutated BRCA1 (5396 + 1G > A in 
the splice donor site of exon 20) (http://research.nhgri.nih.
gov/bic/) [28] Western blot analysis of FANCM expression 
showed that its protein levels were significantly lower in 
the MDA-MD-231 and MDA-MB-436 cell lines compared 
to the  MCF-7 control cell line (Figure 2G). These results 
suggest that miR146a expression in breast cancer cell lines 
is inversely correlated with FANCM protein levels. 
When DNA repair does not properly operate in 
response to DNA ICLs or replication stress, it frequently 
gives rise to genome-wide chromosomal breaks, 
leading to genomic instability. To examine the effect 
of miR146a on genomic integrity, array comparative 
genomic hybridization was performed using human 
fibroblast GM00637 cells after transfecting with miR146a 
or a control miRNA. We found that chromosomal 
abnormalities were detected as chromosomal gains 
(dots over 0.5) and losses (dots below -0.5) that were 
widely distributed throughout the entire genome of 
miR146a-expressing cells (Figure 2H and Supplementary 
Figure S5), indicating that overexpressing miR146a causes 
chromosomal instability.
miR146a targeting FANCM impairs FANCD2 
monoubiquitination 
Loss of FANCM leads to reduced FANCD2-
ubiquitination [17, 29]. Therefore, we assessed 
whether overexpressing miR146a interferes with the 
monoubiquitination of FANCD2 in HeLa and GES-1 cells 
following treatment with HU, which causes replication 
stress and activates the FA pathway. Consistent with 
the reduction in FANCM levels, miR146a expression 
in HeLa or GES-1 cells led to a significant decrease 
in monoubiquitinated FANCD2 (FANCD2-Ub) 
level, compared to a control miRNA (Figure 3A and 
Supplementary Figure S6A, respectively). The effects 
of miR146a were effectively reversed by co-transfecting 
anti-miR146a (Figure 3A), or by expressing exogenous 
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Figure 2: miR146a directly targets FANCM. (A) Schematic diagrams show the sequence and position of predicted miR146a 
binding sites in the FANCM 3′UTR. Single- (M1 and M2) and double- (M3) deletion mutations of the miR146a target sites were shown. 
The seed resion of miR146a is in red. (B) FANCM 3′UTR-WT and FANCM 3′UTR-MT1-3 were cotransfected with miR146a into HeLa 
cells. Luciferase activity was measured 24 h after transfection. Data represent the mean ± SD (n = 3); **P < 0.01. (C) HeLa cells were 
cotransfected with the FANCM 3′UTR luciferase reporter vector along with the candidate miRNAs, which were predicted by Targetscan 
v6.2, or the miRNA-negative control (miR-Ctrl). Results are shown as the mean ± SD (n = 3). (D) The levels of FANCM protein were 
measured by western blotting after transfection of miR146a into a number of cell lines as indicated. (E) Western blot analysis using cell 
extracts was performed to detect cellular levels of FANCM and BRCA1 after transfecting indicated cells with miR146a (top). In parallel, 
the transfected cells were subjected to RNA extraction, followed by RT-qPCR to measure the amount of miR146a after transfection. The 
relative amount of miR146a was quantified and shown as the mean ± SD (n = 3); **P < 0.01 (bottom). (F) Expression of FANCM mRNA 
in miR146a transfected cells was quantitated using real-time qPCR. Results are shown as the mean ± SD (n = 3); **P < 0.01. (G) Three 
different breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-436, were cultured and cell extracts were analyzed for evaluating 
miR146a (left) and FANCM expression (right) using Western blotting and RT-qPCR, respectively. Results are shown as the mean ± 
SD (n = 3); **P < 0.01. (H) Array CGH profiles of human fibroblast GM00637 cells transfected with miR146a versus control miRNA. 
Chromosomal regions above or below the red dotted line indicate gains or losses of corresponding genomic positions, respectively.
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FANCM cDNA that does not harbor the miR146a-
binding 3′UTR (Figure 3B), suggesting that the effects 
are specific to miR146a and FANCM. Consistent with 
these results, both HeLa and GES-1 cells transfected with 
miR146a exhibited defective formation of FANCD2 foci 
compared to cells containing control miRNA, as shown 
by the decreased number of cells with foci (>5 foci) and 
these effects were rescued by anti-miR146a or FANCM 
cDNA expression (Figure 3C, 3D and Supplementary 
Figure S6B). These findings suggest that reduced 
FANCM caused by miR146a leads to impaired FANCD2 
monoubiquitination and FANCD2 foci formation. 
In addition to playing a role in inducing FANCD2-
monoubiquitination, FANCM is also required for inducing 
replication protein A (RPA) phosphorylation and Chk1 
activation in response to ICL-inducing agents [23, 24]. 
Consistent with this finding, expressing miR146a led to 
reduced phosphorylation of Chk1 and RPA, which was 
reversed by FANCM cDNA or anti-miR146a expression 
(Figure 3E and 3F, respectively). These results confirm 
that miR146a expression influences the physiological 
functions of FANCM during DDR. 
miR146a attenuates replication fork restart
Given the known roles of FA proteins in modulating 
replication fork recovery and DNA replication origin 
firing, we determined the effects of miR146a on 
replication fork restart. To this end, we analyzed the DNA 
fiber spreading patterns of miR146a-transfected GES-1 
cells after pulse-labeling the cells sequentially with IdU 
(green fluorescence) and CldU (red fluorescence) before 
and after 5-h HU treatment, respectively (Figure 4A). The 
results showed that nascent CldU tract length distribution 
from stalled replication forks was  mainly shorter tracts in 
miR146a-expressing cells compared to control miRNA-
transfected cells (Figure 4B), indicative of attenuated 
replication fork restart. This miR146a effect is consistent 
with a previous study demonstrated that FANCM-deficient 
cells exhibited defective replication fork restart [30]. 
Activation of NF-κB recapitulates miR146a 
expression in suppressing the FA pathway
There is a wealth of evidence supporting the fact 
that NF-κB up-regulates miR146a expression in various 
cell types such as those involved in immune responses 
and in cancer development [4–6]. To test whether the 
effects of miR146 overexpression described above could 
be recapitulated by NF-κB activation, we analyzed the 
effects of overexpressing the NF-κB RelA/p65 subunit 
after transfecting HeLa or GES-1 cells with the RelA/
p65 expression construct. First, RT-qPCR confirmed that 
the overexpressed p65 subunit significantly upregulated 
miR146a expression compared to the control vector, 
indicating that overexpressed RelA/p65 was successfully 
integrated into the active dimeric form of NF-κB to 
transactivate miR146a transcription (Figure 5A). NF-
κB activation in HeLa cells through p65 overexpression 
was also confirmed by the NF-κB luciferase assay, where 
transcription of the firefly luciferease was turned on by 
the binding of activated NF-κB to its cis-acting element 
in the promoter of this reporter gene (Supplementary 
Figure S7). These results suggest that overexpressing 
p65 functionally mimics NF-κB activation. Indeed, like 
miR146a, p65 overexpression in HeLa cells inhibited 
expression of the luciferase reporter gene carrying wild 
type FANCM 3ʹ-UTR, whereas co-transfection with the 
p65 construct and anti-miR146a alleviated this inhibitory 
effects of NF-κB (Figure 5B), indicating that the effects 
of NF-κB on FANCM are exerted via miR146a. Western 
blot analysis showed a prominent reduction in FANCM 
protein levels, upon overexpression of the p65 subunit, 
which was recovered by co-transfection of p65 and 
anti-miR146a (Figure 5C). Consistent with the reduced 
FANCM levels, overexpressing p65 led to a reduction 
in FANCD2 monoubiquitination (Figure 6A) and foci 
formation (Figure 6B) in HeLa and GES-1 cells. These 
phenotypes were reversed by co-transfection with anti-
miR146a, indicating that the effect of NF-κB on FANCD2 
monoubiquitination and foci formation rely on the 
regulatory axis of NF-κB-miR146a-FANCM. Consistent 
with the role of FANCM in the checkpoint response, p65 
overexpression led to decreased Chk1 (Ser317) and RPA 
phosphorylation, which was reversed by an antagomir 
of miR146a (Figure 6C). Similar to what we observed 
in miR146a-transfected cells, p65 overexpression led 
to delayed recovery from a stalled replication fork, as 
demonstrated by the shortening of red fluorescent CldU 
tracts in p65-overexpressing cells compared to control 
cells (Figure 6D). 
We found that p65 overexpression strongly induced 
γ-H2AX foci, and interestingly, the co-expression of anti-
miR146a reduced the phenotype, in HeLa and GES-1 
cells (Figure 6E). Consistent with the increased damage, 
p65-overexpressing cells were sensitive to HU treatment, 
and the effects were partially or largely alleviated by 
anti-miR146a treatment (Figure 6F). These data suggest 
that aberrantly overexpressed NF-κB promotes genomic 
instability by up-regulating miR146a, which suppresses 
FANCM expression. 
H. pylori mediates down-regulation of FANCM
NF-κB is constitutively activated during 
inflammatory responses triggered by H. pylori infection 
[7–9, 31]. In addition, miR146a was recently identified 
as a target gene upregulated by H. pylori infection [32, 
33]. Therefore we postulated that H. pylori infection 
may affect FANCM protein levels by upregulating 
NF-κB and miR146a in the GES-1 cells. First, to confirm 
that the inflammatory responses in GES-1 cells were 
induced by H. pylori infection, we assessed the cellular 
level of the interleukin (IL)-8 transcript using RT-qPCR 
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Figure 3: Effect of miR146a on FANCD2 monoubiquitination and the FA pathway. (A and B) HeLa cells were transfected 
with miR146a in the absence or presence of anti-miR146a (A) or miR146a-insensitive FANCM cDNA (B). After a 48 h transfection, the cells 
were treated with 5 mM HU for 5 h. The protein levels of FANCM and FANCD2 were measured by western blotting. Monoubiquitinated 
FANCD2 is indicated as the upper band of doublet protein bands corresponding to FANCD2. (C and D) After HeLa cells underwent the 
same treatment as (A and B) cells were analyzed for FANCD2 foci formation. DAPI was used for nuclear staining. Results are shown as 
the mean ± SD (n = 3); **P < 0.01. (E and F) Indicated cells were treated with 5 mM HU for 5 hr. Cell lysates were analyzed by Western 
blotting with antibodies against pCHK1-S317, CHK1, pRPA-S4/8, and RPA.
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and verified that its cellular level increased by ~80-folds 
after H. pylori infection compared to an untreated control 
(Supplementary Figure S8). IL-8 is one of the downstream 
genes whose expression is turned on by activated NF-κB 
when H. pylori infects gastric mucosa epithelial cells 
[34–36]. Next, to determine the cellular FANCM level, 
GES-1 cell lysates were analyzed by western blotting after 
24 h of H. pylori infection. Consistent with the results 
from p65 overexpression in Figure 5C, FANCM protein 
levels were notably down-regulated in H. pylori-infected 
cells compared to untreated control cells (Figure 7A, left). 
Parallel RT-PCR analysis revealed that miR146a was up-
regulated by H. pylori infection by ~3.5 fold compared 
to the control (Figure 7A, right). Importantly, the effects 
of H. pylori infection on FANCM expression were 
alleviated by the simultaneous treatment of anti-miR146a 
(Figure 7B), suggesting that these effects were largely due 
to miR146a expression. 
Consistent with the reduction in FANCM levels, 
FANCD2 monoubiquitination and foci formation were 
reduced upon H. pylori infection (Figure 7C). In contrast, 
the effects of H. pylori on FANCD2 were largely reversed 
by transfecting anti-miR146a during H. pylori infection, as 
shown by recovery of both FANCD2 monoubiquitination 
and foci formation (Figure 7D). These findings indicate 
that H. pylori-induced inflammatory responses down-
regulate FANCM expression by increasing cellular 
miR146a, whose expression is under the control of NF-κB.
DISCUSSION
In this study, we demonstrated that FANCM is 
a direct target of miR146a. Through bioinformatic 
searches, we identified the 3′UTR of FANCM as a binding 
site of miR146a, and confirmed this experimentally. 
Overexpression of miR146a suppressed the steady state 
Figure 4: Effect of miR146a on replication fork restart. (A) Schematic of a single DNA fiber analysis is depicted. For DNA fiber 
analysis, after being transfected with miR146a or a control miRNA, GES-1 cells were labeled with IdU for 20 min, followed by exposure 
to HU for 5 hr and chased with CldU for 40 min. (B) Representative images of spread DNA fibers from miR146a-expressing cells versus 
control cells (top). Nascent track length distribution curves were plotted after measuring the length of CldU tracts from DNA fibers with 
two consecutive colors of green (IdU) and red (CldU). 
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level of FANCM, which was reversed by an antagomir. 
We showed that miR146a overexpression disrupted 
the several known FANCM-dependent processes, such 
as: FANCD2 monoubiquitination/foci formation, the 
FANCM-mediated checkpoint response, replication 
fork stability, and cellular resistance to cisplatin and 
HU. miR146a overexpression also led to the reduced 
RAD51 foci formation and increased double-strand 
Figure 5: Effect of NF-κB on FANCM expression. (A) HeLa or GES-1 cells were transfected with the p65 expression construct and 
miR146a levels in the indicated cells were determined using RT-qPCR analysis. Results are shown as the mean ± SD (n = 3); **P < 0.01. 
(B) Luciferase reporter gene construct carrying the wild type or mutated 3ʹ-UTR of FANCM was cotransfected with p65 cDNA or p65 
cDNA plus anti-miR146a, as well as a control vector into HeLa cells. Luciferase activity was measured 24 hours after the transfection. 
Data represent the mean ± SD (n = 3); **P < 0.01. (C) HeLa or GES-1 cells were transfected with p65 construct in a combination of 
Anti-miR146a or a control miRNA, and indicated protein levels were determined by western blotting (top). Quantitative densitometry of 
FANCM protein expression is shown below, expressed as the mean ± SD (n = 3).
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Figure 6: NF-κB reiterating miR146a function in the FA pathway and replication fork restart. (A) Two days after 
transfection of cells with p65 cDNA and anti-miR146a in combination as indicated, cells were treated with 5 mM HU for 5 h. The levels 
of FANCM and p63 proteins, and FANCD2 ubiquitination were measured by western blotting. (B) After undergoing the same treatment as 
(A) HeLa cells were analyzed for FANCD2 foci formation. Results are shown as the mean ± SD (n = 3); **P < 0.01. (C) Under the same 
conditions described in (A) cell lysates were analyzed by western blotting with antibodies against pCHK1-S317, CHK1, pRPA-S4/8, RPA, 
and GFP.  Right, quantitation of pCHK1-S317 and pRPA-S4/8 expression. Results are shown as the mean ± SD (n = 3). (D) GES-1 cells 
transfected with p65 construct were applied to DNA fiber analysis. Resulting images of DNA fibers of p65-overexpressing cells compared 
with control cells (top). CldU tract length distribution was determined (bottom). (E) HeLa or GES-1 cells with the same treatment as A were 
subjected to γ-H2AX detection. Results are shown as the mean ± SD (n = 3); **P < 0.01. (F) HeLa and GES-1 cells were transfected with 
p65 construct and Anti-miR146a in combinations as indicated and were treated with different doses of HU for 5 hr. Cell survival thereafter 
was measured using clonogenic survival assay. Results are shown as the mean ± SD (n = 3); **P < 0.01.
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break formation, although these phenotypes could be 
attributed to both impaired FANCD2 activation as well 
as BRCA1 expression. BRCA1 was previously reported 
to be a target of miR146a in a study which showed that 
miR146a overexpression reduced HR repair by BRCA1 
downregulation [27]. Thus, we used BRCA1 as an 
internal control throughout our studies. Interestingly, we 
found that the effects of miR146a  were recapitulated by 
overexpressing the p65 subunit of NF-κB, and that these 
effects  were significantly reversed by the concomitant 
expression of anti-miR146a, suggesting that the effects 
caused by the NF-κB activation are largely due to 
miR146a. In order to utilize a more physiological inducer 
of miR146a expression, we employed H. pylori infection 
as a tool. Indeed, H. pylori led to a significant induction 
of miR146a, as well as reduced levels of FANCM and 
FANCD2 activation, which were reversed by anti-
miR146a. Thus, our findings show that genome integrity 
is influenced by the functional link among pathogen-
induced inflammation, NF-κB, and miR146a. 
Figure 7: H. pylori-mediated FANCM regulation. (A) After infection of GES-1 cells with H. pylori, FANCM and BRCA1 protein levels 
were determined by western blotting (left). The effect of H. pylori on miR146a was determined  by RT-qPCR (right). Results are shown as 
the mean ± SD (n = 3); **P < 0.01. (B) GES-1 cells infected with H. pylori were transfected with anti-miR146a, and FANCM and BRCA1 
protein levels were determined by western blotting. (C) H. pylori -infected GES-1 cells were treated with 5 mM HU for 5 hours, FANCD2 
monoubiquitination (left) and its foci forming activity (right) were examined  by western blotting and immunostaining, respectively. Data 
respresent the mean ± SD (n = 3). **P < 0.01. (D) H. pylori-infected GES-1 cells were transfected with anti-miR146a and treated with 
5 mM HU for 5 hours. FANCD2 monoubiquitinating activity (left) and subsequent foci formation (right) were measured by western blotting 
and fluorescent cell staining, respectively. Results are shown as the mean ± SD (n = 3). **P < 0.01.
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In light of the fact that implication of miR146a 
in tumorigenesis has been heavily discussed [5, 6, 
26, 27, 37], our results further strengthen the notion 
that the aberrant expression of miR146a can increase 
tumorigenesis. Our finding that the breast cancer cell 
lines expressing a high level of miR146a failed to express 
the FANCM protein is particularly intriguing. Our work 
shows that the downregulation of FANCM at least in 
part contributes to the role of miR146a in compromising 
genome integrity. Although the statistically significant 
inverse correlation between miR146a and FANCM needs 
more extensive comparative studies in various types of 
cancer cells with clinical manifestation, our study provides 
the first line of evidence showing a negative correlation 
between endogenous miR146a and FANCM expression in 
breast cancer cell lines.
Our analysis suggests that the miR146a-mediated 
regulation of FANCM may be restricted to primates, based 
on the poorly conserved sequence within the FANCM 
3′UTR. This finding suggests that sequences corresponding 
to the FANCM 3ʹUTR might have undergone massive 
species-specific gene rearrangements such as insertions 
and deletions and base substitutions after speciation since 
early vertebrate evolution [38]. Moreover, the alignment 
of the region spanning two miR146a target sites and their 
flanking regions were not applicable except in primates, 
nor were two target sites detected in the other species than 
primates through a BLAST search. This indicates that a 
regulation strategy for FANCM via miR146a has emerged 
as a relatively recent gain-of-function in the evolutionary 
history of vertebrate FANCM. As per the regulation of the 
FA pathway by miRNA, a several other FA-related genes 
such as BRCA1 and RAD51 were shown to be targeted by 
miRNAs [39–41]. 
Perhaps the most intriguing aspect of our work is the 
connection between pathogenic infection and disruption 
of genome integrity. Pathogens such as H. pylori have 
long been suspected as a potential carcinogen. Individuals 
afflicted with chronic infection of this microbe are at 
high risk for gastric cancer or gastric mucosa-associated 
lymphoid tissue lymphoma [42–44]. We found that miR146a 
expression was up-regulated by both H. pylori infection 
and NF-κB activation, the latter of which is regarded as a 
critical link between inflammation and cancer. While the 
contribution of inflammatory cytokines to inflammation-
linked cancer susceptibility is now widely accepted, the 
DNA damage accompanying chronic inflammation has 
gradually gained attention as it can lead to gene mutations 
that  can cause cancer [28, 45]. During inflammation, pro-
inflammatory cytokines such as TNF-a, IL-1β, and IL-6, 
serve as  the main way of communication between cells in 
different tissues and immune cells and trigger intracellular 
signaling cascades whose main feature is NF-κB activation 
[46–49]. miR146a is a well-known NF-κB-dependent gene 
but has also been reported to downregulate several signaling 
mediators involved in inflammatory responses such as TNF 
receptor-associated factor 6 (TRAF6) and IL-1 receptor-
associated kinase 1 (IRAK1) that are located upstream of 
NF-κB activation, thus exerting a negative feedback loop 
for modulating NF-κB activity [4, 50, 51], which prevents 
constitutive activation of NF-κB during inflammatory 
response. On the other hand, NF-κB can be activated 
during the host cell response to bacterial infection (e.g., 
H. pylori in our study). H. pylori’s cell wall component 
peptidoglycan which is injected into gastric epithelial 
cells during infection, is recognized by the intracellular 
pattern recognition molecule, NOD1, eliciting the signaling 
cascade to activate NF-κB, which occurs independently 
of cytokine-triggered signaling cascades [7, 33, 52]. Our 
results demonstrate that GES-1 cells successfully responded 
to H. pylori infection, expressing IL-8 whose transcription 
is activated by NF-κB. Although additional studies on H. 
pylori-induced dampening of FA pathway activation in more 
physiological settings are needed, our finding that H. pylori 
influenced FANCM levels provides an understanding of the 
mechanism behind H. pylori-linked carcinogenesis. There 
are several ways to explain the mechanisms underlying 
genomic instability caused by H. pylori: i) H. pylori 
infection impairs mismatch repair and base excision repair 
by down-regulating component molecules [53, 54]; ii) 
H. pylori infection generates reactive oxygen species, 
causing oxidative damage of the DNA and genomic 
instability [55]; iii) specific oncogene activation in 
precancerous patient tissue samples is associated with 
double-strand breaks caused by H. pylori infection and 
the activation of DNA-damage checkpoints [56–58]. 
The disturbance of the FA pathway by H. pylori may not 
be critical for maintenance of the genomic integrity of 
terminally-differentiated gastric epithelial cells in the 
G
0
 phase. However, this pathogen would compromise 
the genomic integrity if the infection occurs in actively 
proliferating gastric epithelial progenitors [59]. Subsequent 
exposure to genotoxins such as ICL-inducing agents, which 
gastric epithelial cells have even higher chance to take 
up as food ingredients may also foster the gastric cancer 
development. 
In summary, we demonstrated that miR146a 
decreased the FANCM protein level, thereby disabling 
FANCD2 activation upon DNA damaging agent treatment. 
Furthermore, we uncovered an important role of miR146a 
in NF-κB- and H. pylori- induced genomic instability. Our 
work suggests that dysregulated NF-κB activation and 
persistent H. pylori infection, both of which upregulate 
miR146a expression, can compromise genome integrity 
and potentially contribute to tumorigenesis in part by 
suppressing the DDR involving FANCM. 
MATERIALS AND METHODS
Cell culture and treatment
The human cervical adenocarcinoma cell line HeLa, 
immortalized human normal gastric epithelial mucosa cell 
line GES-1, human gastric carcinoma cell line HGC-27, 
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and human osteosarcoma bone morphogenetic cell line 
U2OS were purchased from the American Type Culture 
Collection (ATCC, Rockville, MD) and maintained as 
recommended: all of the cell types were cultured in 
Dulbecco’s Modified Eagle’s medium (Invitrogen, CA) 
supplemented with 10 % heat-inactivated fetal bovine 
serum (Invitrogen), 100 units/ml penicillin, and 100 µg/
ml streptomycin sulfate (Invitrogen), and maintained 
in a humidified incubator containing 5% CO
2
 at 37oC. 
To induce replication fork stalling or ICL damage, 
exponentially growing cells were exposed to 5 mM HU 
or 1 mM cisplatin and allowed to recover at 37oC for 5 h. 
H. pylori culture and infection
The H. pylori strain 26695 was obtained from 
HpKTCC (H. pylori Korean Type Culture Collection, 
Jinju, South Korea). The bacteria was grown in Brucella 
broth containing 10% fetal bovine serum, 10 µg/
ml vancomycin, 25 µg/ml nalidixic acid and 5 µg/ml 
amphotericinB, and maintained in a humidified incubator 
containing 10% CO
2
 at 37oC. GES-1 cells were seeded 
at 10 × 105 cells/100 mm plate and grown to 70–80% 
confluency. H. pyroli infected the GES-1 cells at 100 
MOI multiplicity of infection for 24 h. The infection was 
monitored by the release of IL-8.
Antibodies
The antibodies used for Western blotting were 
as follows: FANCM (sc-98710), FANCD2 (sc-20022), 
BRCA1 (sc-642), β-actin (sc-47778; Santa Cruz, CA), 
RPA (NA18; Calbiochem, CA), phosphor-RPA(S4/
S8) (A300-245A;  Bethyl Lab), CHK1 (2G1D5; Cell 
Signaling, MA) and phosphor-CHK1(S317) (AF2054; 
R&D System, MN). FANCD2 foci were detected by 
immunofluorescence staining using an anti-FANCD2 
antibody (AB2187; Abcam). γ-H2AX foci were 
visualized by immunofluorescence staining using anti-γ-
H2AX mouse monoclonal antibody (JBW301; Upstate 
Biotechnology, NY).  RAD51 foci were detected by 
immunofluorescence staining using mouse monoclonal 
anti-RAD51 (14B4) (ab213; Abcam, MA). 
miRNA luciferase reporter assay 
Segments of the 3′UTR of FANCM containing 
putative miR146a binding sites were cloned into pMIR-
REPORT firefly luciferase vector (Applied Biosystems, 
CA). Deletion mutants of predicted miR146a binding 
sites were made using the GENEART Site-Directed 
Mutagenesis kit (Invitrogen). For the luciferase activity 
assay, pMIR-REPORT luciferase vectors containing wild 
type or mutant 3′UTRs of FANCM and pRL-TK vector 
containing Renilla luciferase as a transfection control 
were co-transfected into HeLa cells using Lipofectamine 
2000 (Invitrogen), and subsequently, the same cells 
were transfected with miR146a, anti-miR146a or RelA/
p65 expression construct. After 24 h of transfection, the 
luciferase assay was performed using the dual luciferase 
reporter assay system (Promega, WI) according to the 
manufacturer’s instructions. Luciferase activity was 
quantified using a luminometer (Glomax, Promega). 
NF-κB luciferase reporter assay
HeLa cells were seeded at a concentration of 
5 × 105 cells/well in 24-well plates. After overnight 
culture and reaching 80% confluence, the cells in 
each well were transiently transfected with 1 μg DNA 
consisting of pGL4.32 (luc2P/NF-κB-RE/Hygro) as a 
reporter (Promega), pRL-TK, as well as the RelA/p65 
expression construct, in serum-free medium according to 
the manufacturer’s protocol. After 12 h, the transfection 
mix was removed and replaced with complete medium. 
Twenty-four hours after co-transfection, cells were 
harvested and luciferase activity was determined using the 
Luciferase Assay System (Promega, E1500). 
miRNA and plasmid transfection
Hsa-miR146a duplex and negative control miRNA 
were purchased from Bioneer (Daejeon, South Korea). 
Cells were transfected with 50 nM miRNA using 
lipofectamine RNAiMax (Invitrogen) according to the 
manufacturer’s instructions. For rescue experiments, a 
miR146a inhibitor (anti-miR146a) was used. Full-length 
BRCA1 and FANCAM were cloned into pcDNA3-HA and 
pCMV-Flag vector, respectively, to generate mammalian 
expression vector. For experiments measuring NF-κB-
mediated miR146a regulation, pcDNA HA-p65 vector 
was used. pcDNA-HA empty vector and scrambled 
oligonucleotide were used as negative controls. 
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl 
[pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM 
dithiothreitol, 1 mM phenylmethanesulfonyl fluoride, 
10 µg/ml leupeptin and 10 µg/ml aprotinin). Equal 
amounts of cell or tissue extracts were separated by 
6–12% SDS-PAGE gels followed by electrotransfer onto 
a PVDF membrane (Life Sciences, NJ). Western blots 
were performed by using the appropriate primary and 
secondary antibodies. The amounts of FANCM protein 
were quantified using Scion Image software (Scion 
Corp., MD).
Immunofluorescence staining
Cells cultured on cover slips were treated with 
5 mM hydroxyurea or 1 mM cisplatin, allowed to recover 
for adequate times and then fixed in 4% paraformaldehyde 
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and 98% methanol, followed by permeabilization with 
0.3% Triton X-100. Then coverslips were blocked in 5% 
BSA in PBS and immunostained with primary antibodies 
and secondary antibodies conjugated with Alexa Fluor 488 
(green, Molecular Probe, CA) or Alexa Fluor 594 (red, 
Molecular Probe). After washing, the coverslips were 
mounted onto slides using a Vectashield mounting medium 
with DAPI (Vector Laboratories, CV). Fluorescence 
images were taken using a confocal microscope (Zeiss 
LSM 510 Meta; Carl Zeiss) and analyzed with Zeiss 
microscopic imaging software ZEN (Carl Zeiss). 
Array comparative genomic hybridization 
analysis
Array comparative genomic hybridization (CGH) 
analysis was performed using the Nimblegen Human 
CGH 12 × 135 K whole-genome tiling v3.1 Array (Agilent 
Technologies, CA). Human genomic DNA (1 µg) from 
human fibroblast GM00637 cells which were transfected 
with miR146a and reference DNA samples from control 
cells were independently labeled with fluorescent dyes 
(Cy3/Cy5), co-hybridized at 65°C for 24 h, and then 
subjected to the array. The hybridized array was scanned 
using NimbleGen MS200 scanner (NimbleGen Systems 
Inc., WI) with 2 µm resolution. Log
2
-ratio values of the 
probe signal intensities were calculated and plotted versus 
genomic position using Roche NimbleGen NimbleScan 
v2.5 software. Data are displayed and analyzed in Roche 
NimbleGen SignalMap software and CGH-explorer v2.55.
DNA fiber analysis
GES-1 cells were labeled with 25 μM 5-iodo-2ʹ-
deoxyuridine (IdU) for 20 min, followed by exposure to 
5 mM HU for 5 h, and chased with 250 μM 5-chloro-2ʹ-
deoxyuridine (CldU) for 40 min. After labeled cells were 
harvested, DNA fibers were spread as previously described 
[60] before fluorescent staining for IdU and CldU tracts 
(with primary antibodies for IdU, (mouse α-BrdU (Sigma) 
at 1:25 dilution); and for CldU (rat α-BrdU (Sigma) at a 
1:400 dilution) and secondary antibodies: anti-mouse IgG 
conjugated with AlexaFluor 488 and Cy3-conjugated 
anti-rat IgG, respectively, from Invitrogen). Fibers were 
visualized under a confocal microscope (Zeiss LSM 510 
Meta) and analyzed using Zeiss microscopic imaging 
software ZEN (Carl Zeiss). 
Clonogenic cell survival assay
After treatment of HU or cisplatin at different 
concentrations for 2 h, 5 ×102 cells were immediately 
seeded on 60-mm dishes in triplicate and grown for 2~3 
weeks at 37oC to allow colonies to form. Colonies were 
stained with 2% methylene blue/50% ethanol and were 
counted. The fraction of surviving cells was calculated as 
the ratio of the number of colonies to the cell number at 
the time of seeding for the plating efficiency of treated 
cells over untreated cells. Cell survival results are reported 
as the mean value ± SD for three independent experiments. 
RNA extraction and reverse rranscription-
quantitative real-time PCR (RT-qPCR)
Total RNA was isolated from cultured cells, 
mouse tissues, and prostate cancer samples using TRIzol 
reagent (Invitrogen). For quantitation of FANCM and 
IL-8 mRNA, cDNA was synthesized using 1 μg total 
RNA, random hexamer (Promega) and M-MLV reverse 
transcriptase (Invitrogen). Real-time PCR analysis was 
performed using the SYBR green-based fluorescent 
method (SYBR premix Ex Taq kit, TaKaRa Bio) and 
the MX3000P® qRT-PCR system (Stratagene, CA) with 
specific primers. Primers used for real-time PCR are as 
follows: fancm forward, 5ʹ-tgctcttcacaggagtggtg-3ʹ and 
fancm reverse, 5ʹ-gggcacacaggaacttgact-3ʹ; IL-8 forward, 
5ʹ-TTGGCAGCCTTCCTGATTTC-3ʹ and reverse 
5ʹ-AACTTCTCCACAACCCTCTG-3ʹ. To quantify 
miRNAs, cDNA was synthesized using Mir-XTM miRNA 
first-strand synthesis and SYBR qRT-PCR kit (Clontech) 
according to the manufacturer’s instructions. Has-
miR146a-MI0000477 was used as primer for real-time 
qPCR. The quantity of transcripts was calculated based 
on the threshold cycle (C
t
) using the delta-delta C
t
 method 
that measures the relative of a target RNA between two 
samples by comparing them to a normalization control 
RNA (gapdh or U6).
Statistical analysis
Data in all of the experiments are presented as the 
mean ± standard deviation (SD) Statistical comparisons 
were performed using two-tailed paired Student’s t-test, 
where p < 0.01(**) was considered statistically significant. 
Analyses were performed using GraphPad Prism software 
(GraphPad software) and Excel (Microsoft). 
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